Promis Neurosciences (NASDAQ:PMN) Upgraded by Zacks Research to “Hold” Rating

Zacks Research upgraded shares of Promis Neurosciences (NASDAQ:PMN) to a hold rating in a research report report published on Tuesday,Zacks.com reports.

Other equities analysts have also recently issued reports about the stock. HC Wainwright reissued a “buy” rating and issued a $18.00 target price on shares of Promis Neurosciences in a research note on Monday. Wall Street Zen raised shares of Promis Neurosciences from a “strong sell” rating to a “sell” rating in a research note on Sunday, May 31st. Finally, Brookline Capital Markets raised shares of Promis Neurosciences to a “strong-buy” rating in a research note on Wednesday, May 20th. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Promis Neurosciences presently has a consensus rating of “Moderate Buy” and an average target price of $26.50.

Promis Neurosciences Trading Up 4.7%

NASDAQ:PMN opened at $10.20 on Tuesday. Promis Neurosciences has a 1-year low of $6.27 and a 1-year high of $39.75. The firm has a fifty day simple moving average of $10.97 and a 200 day simple moving average of $12.04. The stock has a market capitalization of $91.49 million, a PE ratio of -0.70 and a beta of -0.19.

Promis Neurosciences (NASDAQ:PMN) last released its earnings results on Tuesday, May 12th. The company reported ($1.26) earnings per share for the quarter, missing the consensus estimate of ($1.06) by ($0.20). On average, equities analysts predict that Promis Neurosciences will post -4.57 earnings per share for the current fiscal year.

Insider Transactions at Promis Neurosciences

In other Promis Neurosciences news, Director Patrick D. Kirwin purchased 4,000 shares of the business’s stock in a transaction on Wednesday, April 22nd. The stock was acquired at an average price of $11.33 per share, with a total value of $45,320.00. Following the acquisition, the director directly owned 4,653 shares of the company’s stock, valued at $52,718.49. This trade represents a 612.56% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. 1.50% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Promis Neurosciences

Several hedge funds have recently added to or reduced their stakes in the business. Seven Fleet Capital Management LP acquired a new stake in Promis Neurosciences during the 1st quarter valued at $135,000. ADAR1 Capital Management LLC acquired a new stake in Promis Neurosciences during the 1st quarter valued at $1,211,000. Citadel Advisors LLC lifted its holdings in Promis Neurosciences by 168.1% during the 3rd quarter. Citadel Advisors LLC now owns 170,079 shares of the company’s stock valued at $72,000 after purchasing an additional 106,650 shares during the last quarter. Ally Bridge Group NY LLC lifted its holdings in Promis Neurosciences by 66.1% during the 1st quarter. Ally Bridge Group NY LLC now owns 414,219 shares of the company’s stock valued at $5,261,000 after purchasing an additional 164,880 shares during the last quarter. Finally, Yu Fan acquired a new stake in Promis Neurosciences during the 1st quarter valued at $4,188,000. Institutional investors and hedge funds own 50.13% of the company’s stock.

Key Promis Neurosciences News

Here are the key news stories impacting Promis Neurosciences this week:

• Positive Sentiment: HC Wainwright reiterated a Buy rating on Promis Neurosciences and maintained an $18.00 price target, signaling meaningful upside versus the current trading level. Source: MarketBeat PMN analyst updates
• Positive Sentiment: HC Wainwright raised its FY2026 EPS estimate for PMN, which can be viewed as a modest improvement in the medium-term earnings outlook. Source: MarketBeat PMN analyst updates
• Neutral Sentiment: Zacks Research upgraded Promis Neurosciences to Hold, which is better than a downgrade but does not point to strong near-term upside. Source: Zacks.com
• Negative Sentiment: Several HC Wainwright quarterly EPS estimates for 2026 and 2027 are still deeply negative, and the firm lowered its Q4 2026 estimate, which may weigh on sentiment. Source: MarketBeat PMN analyst updates
• Negative Sentiment: The stock was also highlighted in an article noting it was down sharply, suggesting investors are reacting to the weak earnings profile and ongoing volatility. Source: AAII article

About Promis Neurosciences

Promis Neurosciences, Inc is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel therapeutics for central nervous system disorders. The company’s research programs target cognitive impairment and other neurological symptoms associated with diseases such as Alzheimer’s disease and multiple sclerosis.

Leveraging a proprietary small‐molecule discovery platform, Promis Neurosciences advances both preclinical and early clinical candidates designed to modulate neural pathways involved in memory, learning and neuroinflammation.